Amer Alshekhlee, MD
Vascular Neurology · Bridgeton, MONPI 1255328100
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,475 of the $3,593 with a category attached, or 68.9%. 13 manufacturers reported payments, led by AbbVie at 25.8% of the total. Reporting peaked in 2023 at $1,241 and has fallen 70.3% since, to $369 in 2025.
Across 103 payments — averaging $34.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$928
- Janssen Research & Development, LLC$922
- Imperative Care, Inc$678
- Stryker$209
- UCB, Inc.$159
- Penumbra, Inc.$139
- plus $559 from 7 others
Across 58 payments — averaging $1891.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Penumbra, Inc.$48K
- Janssen Research & Development, LLC$44K
- Microvention, Inc.$10K
- Novo Nordisk AS$3K
- Stryker$3K
- Guerbet LLC$582
- plus $582 from 1 others
What the payments were for
- Travel & lodging$1,11931%
- Food & beverage$2,47569%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 66 | $928 |
| Janssen Research & Development, LLC | 8 | $922 |
| Imperative Care, Inc | 10 | $678 |
| Stryker | 5 | $209 |
| UCB, Inc. | 1 | $159 |
| Penumbra, Inc. | 3 | $139 |
| AstraZeneca | 1 | $120 |
| Edwards Lifesciences | 1 | $116 |
| Novo Nordisk | 1 | $112 |
| Sanofi | 1 | $100 |
| Microvention, Inc. | 3 | $49 |
| Inspiremd Ltd | 1 | $31 |
| Johnson & Johnson | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few vascular neurology providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $23,578 |
| ClopidogrelClopidogrel Bisulfate | 164 | $1,105 |
| Levetiracetam | 31 | $505 |
| Atorvastatin Calcium | 24 | $224 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Bridgeton
- Chizoba EzepueBridgeton$8K
- Adnan QureshiColumbia$60K
- Guillermo LinaresSaint Louis$11K
- Camilo GomezColumbia$6K
- Weston GordonSaint Louis$5K
- Chike IlorahSaint Louis$5K
- Brandi FrenchColumbia$3K
- Abdallah AmirehSaint Joseph$3K
- Randall EdgellSaint Louis$687
- Firas Al ShakarchiKansas City$681
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.